公开(公告)号：US20250064916A1

公开(公告)日：2025-02-27

申请号：US18795336

申请日：2024-08-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Sylvie BERTHOLET GIRARDIN ,  Arun KUMAR

IPC: A61K39/145 ,  A61K39/00

Abstract: The present invention is in the field of treating and/or preventing viral infections. In particular, the present invention relates to immunogenic or pharmaceutical compositions comprising self-replicating RNA molecules that encode influenza virus antigens for treating and/or preventing influenza infections.

公开(公告)号：US20250042951A1

公开(公告)日：2025-02-06

申请号：US18895059

申请日：2024-09-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20250009874A1

公开(公告)日：2025-01-09

申请号：US18650745

申请日：2024-04-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Enrico MALITO ,  Sumana CHANDRAMOULI ,  Andrea CARFI ,  Matthew BOTTOMLEY

IPC: A61K39/245 ,  A61K47/64 ,  C07K14/005

Abstract: Described are mutant, human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

公开(公告)号：US12180512B2

公开(公告)日：2024-12-31

申请号：US18453078

申请日：2023-08-21

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Stefano Colloca

IPC: C12N15/00 ,  A61K39/235 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

Abstract: A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.

公开(公告)号：US20240383949A1

公开(公告)日：2024-11-21

申请号：US18435026

申请日：2024-02-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Enrico MALITO ,  Matthew James BOTTOMLEY ,  Andrea CARFI ,  Sumana CHANDRAMOULI ,  Kate LUISI

IPC: C07K14/045 ,  A61K38/00 ,  A61K39/245

Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

公开(公告)号：US12138307B2

公开(公告)日：2024-11-12

申请号：US18353172

申请日：2023-07-17

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ahmad Taimour Baig ,  Juan Jose Diaz Garcia ,  Chad Austin Farrenburg ,  Kent Raymond Myers ,  Jeri Kay Sandvick ,  Jeb Yeatts Vandenburg

IPC: A61K36/00 ,  A61K36/185 ,  A61K39/39 ,  A61K39/00

Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ≤0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.

公开(公告)号：US12128096B2

公开(公告)日：2024-10-29

申请号：US17804679

申请日：2022-05-31

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Amirreza Faridmoayer ,  Rainer Follador ,  Stefan Jochen Kemmler ,  Michael Thomas Kowarik ,  Gerald Johann Posch ,  Fabio Serventi

IPC: A61K39/09 ,  A61K39/102 ,  C08B37/00 ,  A61K35/74 ,  A61K38/00 ,  A61K47/36 ,  B01J20/32 ,  C07K9/00 ,  C07K14/315

CPC classification number: A61K39/092 ,  A61K39/102 ,  C08B37/006 ,  A61K35/74 ,  A61K38/00 ,  A61K47/36 ,  B01J20/32 ,  C07K9/005 ,  C07K14/315

Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.

公开(公告)号：US12128094B2

公开(公告)日：2024-10-29

申请号：US17287268

申请日：2019-11-04

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Mario Contorni ,  Mariagrazia Pizza ,  Anja Seubert

IPC: A61P31/04 ,  A61K39/00

CPC classification number: A61K39/0018 ,  A61P31/04 ,  A61K2039/55505

Abstract: The invention provides an immunogenic composition comprising OMVs and (a) acellular pertussis antigen, (b) a tetanus toxoid and (c) a diphtheria toxoid, wherein the OMVs are derived from Bordetella pertussis. The invention also provides compositions for use in a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

公开(公告)号：US20240350410A1

公开(公告)日：2024-10-24

申请号：US18683535

申请日：2022-08-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Rushit LODAYA ,  Patrick POHLHAUS ,  Elizabeth ZECCA ,  Jinjin ZHANG ,  Adora PADILLA ,  Erwan BOURLÈS ,  Julie ENERT

IPC: A61K9/127 ,  A61K9/19 ,  A61K31/7105 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26

CPC classification number: A61K9/1272 ,  A61K9/1271 ,  A61K9/19 ,  A61K31/7105 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26

Abstract: Compositions and methods are provided for stabilization of RNA encapsulated by lipid nanoparticles during lyophilization. Novel lyophilization processes are provided. These techniques may be used to prevent the need for cold chain storage.

公开(公告)号：US12076352B2

公开(公告)日：2024-09-03

申请号：US16973471

申请日：2019-06-18

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Christiane Marie-Paule Simone Jeanne Feron ,  Sandra Giannini

IPC: A61K35/76 ,  C12N7/00

CPC classification number: A61K35/76 ,  C12N7/00 ,  C12N2795/00043 ,  C12N2820/55

Abstract: The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.